Trial · NCT00624650
Hemodynamics and Extravascular Lung Water in Acute Lung Injury
NCT00624650, Phase 2, Completed, Oregon Health and Science University; results first posted 2019-09-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hemodynamics and Extravascular Lung Water in Acute Lung Injury. Trials, record NCT00624650. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00624650
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hemodynamics and Extravascular Lung Water in Acute Lung Injury
- NCT number
- NCT00624650
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 33 participants, actual
- Lead sponsor
- Oregon Health and Science University
- Conditions
- Acute Lung Injury
- Interventions
Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
- First posted
- 2008-02-27
- Last updated
- 2019-09-10
- Results first posted
- 2019-09-10
- Limitations and caveats
- Principal Investigator departed the institution before Primary Outcome Measure analyses were conducted.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water | The first seven days of treatment |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Primary Efficacy Variable Will be the Total Reduction in Measured Lung Water | The first seven days of treatment | The study's Principal Investigator departed the institution before analyses were conducted. OHSU will never have analyses complete for this study. The study device is no longer manufactured. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Modified FACTT (Control) | 17 | |
| Overall Study | STARTED | EVLW | 16 | |
| Overall Study | COMPLETED | Modified FACTT (Control) | 16 | |
| Overall Study | COMPLETED | EVLW | 15 | |
| Overall Study | NOT COMPLETED | Modified FACTT (Control) | 1 | |
| Overall Study | NOT COMPLETED | EVLW | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypernatremia | Renal and urinary disorders | Modified FACTT (Control) | 1 | 17 | |
| other | Hypernatremia | Renal and urinary disorders | EVLW | 2 | 16 | |
| serious | Death | Cardiac disorders | Modified FACTT (Control) | 2 | 17 | |
| serious | Death | Cardiac disorders | EVLW | 5 | 16 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Modified FACTT (Control) | 2 | 17 |
| Total, all-cause mortality | EVLW | 5 | 16 |
| Total, other adverse events | Modified FACTT (Control) | 1 | 17 |
| Total, other adverse events | EVLW | 2 | 16 |
| Total, serious adverse events | Modified FACTT (Control) | 2 | 17 |
| Total, serious adverse events | EVLW | 5 | 16 |
Source ClinicalTrials.gov
Papers78
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Modified FACTT (Control) vs EVLW: deaths from any cause | Trial comparisons |
| Modified FACTT (Control) vs EVLW: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00624650
GET https://conductscience.org/api/trials/v1/NCT00624650/papers?page=2